journal
https://read.qxmd.com/read/39242100/correction-electroconvulsive-therapy-versus-aripiprazole-addition-to-clozapine-in-patients-with-clozapine-resistant-symptoms-emeclo-a-protocol-of-a-single-blind-multicenter-randomized-controlled-feasibility-trial
#1
JOURNAL ARTICLE
Manouk den Toom, Laura Blanken, Inge Horn, Selene Veerman, Joris J B van der Vlugt-Molenaar, Mariken B de Koning, Jan Bogers, John Enterman, Martin de Jonge, Daniela Cianci, Gerardus W J Frederix, Hans J de Haas, Bram W Storosum, Mike Veereschild, Martin Javadzadeh, Peter F J Schulte, Dan Cohen, Jim van Os, Wiepke Cahn, Lieuwe de Haan, Jasper B Zantvoord, Jurjen J Luykx
No abstract text is available yet for this article.
September 6, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39187246/association-study-between-drd2-drd3-genetic-polymorphisms-and-adverse-reactions-in-chinese-patients-on-amisulpride-treatment
#2
JOURNAL ARTICLE
Kankan Qu, Yanan He, Zhongdong Zhang, Yeli Cao, Qiyun Qin, Zhenhe Zhou, Lili Zhen
OBJECTIVE: To determine if the cardiac function and "endocrinium" of Chinese patients are associated with dopamine D2 ( DRD2 ) ( rs6276 ) and DRD3 ( rs6280, rs963468 ) genetic polymorphisms when treated with amisulpride. METHODS: This study enrolled 148 patients with schizophrenia who took amisulpride orally for 8 weeks. DRD2 (rs6276) and DRD3 (rs6280, rs963468) genetic polymorphisms were detected with TaqMan-MGB allelic discrimination. RESULTS: Analysis by multivariate covariance analysis (MANCOVA) showed that after adjusting for age, gender, and the baseline level, the increase in the level of aspartate aminotransferase (AST) and creatine kinase (CK) in the rs6276 AG group was higher than that in the AA and GG groups...
August 26, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39187245/electroconvulsive-therapy-versus-aripiprazole-addition-to-clozapine-in-patients-with-clozapine-resistant-symptoms-emeclo-a-protocol-of-a-single-blind-multicenter-randomized-controlled-feasibility-trial
#3
JOURNAL ARTICLE
Manouk den Toom, Laura Blanken, Inge Horn, Selene Veerman, Joris J B van der Vlugt-Molenaar, Mariken B de Koning, Jan Bogers, John Enterman, Martin de Jonge, Daniela Cianci, Gerardus W J Frederix, HansJ de Haas, Bram W Storosum, Mike Veereschild, Martin Javadzadeh, Peter F J Schulte, Dan Cohen, Jim van Os, Wiepke Cahn, Lieuwe de Haan, Jasper B Zantvoord, Jurjen J Luykx
BACKGROUND: Currently, guidance on the most effective treatment for patients with clozapine-resistant schizophrenia-spectrum disorders (SSD) is lacking. While augmentation strategies to clozapine with aripiprazole and electroconvulsive therapy (ECT) have been demonstrated to be effective in patients with clozapine-resistant schizophrenia spectrum disorders (CRS), head-to-head comparisons between these addition strategies are unavailable. We therefore aim to examine the feasibility of a larger randomized, single-blind trial comparing the effectiveness, cost-effectiveness, and safety of aripiprazole addition vs...
August 26, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39178840/increased-odds-of-cognitive-impairment-in-adults-with-depressive-symptoms-and-antidepressant-use
#4
JOURNAL ARTICLE
Shakila Meshkat, Michelle Wu, Vanessa K Tassone, Reinhard Janssen-Aguilar, Hilary Pang, Hyejung Jung, Wendy Lou, Venkat Bhat
INTRODUCTION: The relationship between antidepressant use and class with cognition in depression is unclear. This study aimed to evaluate the association of cognition with depressive symptoms and antidepressant use (class, duration, number). METHODS: Data from the National Health and Nutrition Examination Survey were examined for cognitive function through various tests and memory issues through the Medical Conditions questionnaire. Depressive symptoms were assessed using the Patient Health Questionnaire-9...
August 23, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39173675/twenty-three-years-of-declining-lithium-use-analysis-of-a-pharmacoepidemiological-dataset-from-german-speaking-countries
#5
JOURNAL ARTICLE
Waldemar Greil, Mateo de Bardeci, Nadja Nievergelt, Sermin Toto, Renate Grohmann, Johanna Seifert, Georgios Schoretsanitis
INTRODUCTION: Pharmacoepidemiological data suggest that lithium prescriptions for bipolar disorder are gradually decreasing, with less attention having been paid to other indications. METHODS: We examined lithium prescriptions between 1994 and 2017 in data provided by the Drug Safety in Psychiatry Program AMSP, including psychiatric hospitals in Germany, Austria and Switzerland. We compared lithium use for different diagnoses before and after 2001 and in three periods (T1: 1994-2001, T2: 2002-2009, and T3: 2010-2017)...
August 22, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39159843/precision-psychiatry-approach-to-treat-depression-and-anxiety-targeting-the-stress-hormone-system-v1b-antagonists-as-a-case-in-point
#6
JOURNAL ARTICLE
Florian Holsboer, Marcus Ising
The future of depression pharmacotherapy lies in a precision medicine approach that recognizes that depression is a disease where different causalities drive symptoms. That approach calls for a departure from current diagnostic categories, which are broad enough to allow adherence to the "one-size-fits-all" paradigm, which is complementary to the routine use of "broad-spectrum" mono-amine antidepressants. Similar to oncology, narrowing the overinclusive diagnostic window by implementing laboratory tests, which guide specifically targeted treatments, will be a major step forward in overcoming the present drug discovery crisis...
August 19, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39089318/sars-cov-2-infection-in-people-addicted-to-illegal-drugs-is-there-a-protective-effect-of-opioid-maintenance-treatment
#7
JOURNAL ARTICLE
Simon Kurzhals, Martin Schäfer, Udo Bonnet, Katrin Isbruch, Stefan Kühnhold, Jörg Timm, Michael Specka, Norbert Scherbaum
INTRODUCTION: People addicted to illegal drugs were discussed as a risk group for SARS-CoV-2 infections, with increased susceptibility and a severe course of infection. METHODS: In this study, the frequency of SARS-CoV-2 infections of drug-dependent persons admitted to inpatient detoxification treatment in five psychiatric hospitals was determined by implementing routine polymerase chain reaction (PCR)-testing at admission (9/2020) up to one year. Main substance-related diagnosis, comorbid respiratory disease, housing situation, and current opioid maintenance treatment (OMT) were documented...
August 1, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/39084319/recreational-cannabis-legalization-no-contribution-to-rising-prescription-stimulants-in-the-usa
#8
JOURNAL ARTICLE
Garrett D Alexander, Luke R Cavanah, Jessica L Goldhirsh, Leighton Y Huey, Brian J Piper
INTRODUCTION: There have been substantial increases in the use of Schedule II stimulants in the United States. Schedule II stimulants are the gold standard treatment for attention-deficit hyperactivity disorder (ADHD), but also carry the risk of addiction. Since the neurocognitive deficits seen in ADHD resemble those of chronic cannabis use, and the rise in stimulant use is incompletely understood, this study sought to determine if recreational cannabis (RC) legalization increased distribution rates of Schedule II stimulants...
July 31, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38917847/a-trajectory-of-long-term-antipsychotic-medication-dosage-in-inpatients-with-severe-behavioral-and-psychological-symptoms-of-dementia-a-retrospective-study
#9
JOURNAL ARTICLE
Teruo Tada, Takefumi Suzuki, Yusuke Iwata, Masaharu Kubota, Koichiro Watanabe, Hitoshi Sakurai
INTRODUCTION: While antipsychotics are often prescribed for behavioral and psychological symptoms of dementia (BPSD), typically on an off-label basis, these medications have serious adverse effects. This study investigated the long-term use of antipsychotics among inpatients with dementia displaying severe BPSD, focusing on how prescriptions change over time. METHODS: Medical charts at Kusakabe Memorial Hospital were retrospectively reviewed from October 2012 to September 2021...
June 25, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38917846/integrative-genetic-variation-dna-methylation-and-gene-expression-analysis-of-escitalopram-and-aripiprazole-treatment-outcomes-in-depression-a-can-bind-1-study
#10
JOURNAL ARTICLE
Farhana Islam, Amanda Lisoway, Edward S Oh, Laura M Fiori, Leen Magarbeh, Samar S M Elsheikh, Helena K Kim, Stefan Kloiber, James L Kennedy, Benicio N Frey, Roumen Milev, Claudio N Soares, Sagar V Parikh, Franca Placenza, Stefanie Hassel, Valerie H Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W Lam, Gustavo Turecki, Jane A Foster, Susan Rotzinger, Sidney H Kennedy, Daniel J Müller
INTRODUCTION: Little is known about the interplay between genetics and epigenetics on antidepressant treatment (1) response and remission, (2) side effects, and (3) serum levels. This study explored the relationship among single nucleotide polymorphisms (SNPs), DNA methylation (DNAm), and mRNA levels of four pharmacokinetic genes, CYP2C19 , CYP2D6 , CYP3A4 , and ABCB1 , and its effect on these outcomes. METHODS: The Canadian Biomarker Integration Network for Depression-1 dataset consisted of 177 individuals with major depressive disorder treated for 8 weeks with escitalopram (ESC) followed by 8 weeks with ESC monotherapy or augmentation with aripiprazole...
June 25, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38897220/management-of-refractory-functional-gastrointestinal-disorders-what-role-should-psychiatrists-have
#11
JOURNAL ARTICLE
Mohsen Khosravi, Abdullah A Alzahrani, Thikra M Muhammed, Ahmed Hjazi, Huda H Abbas, Mervat A AbdRabou, Karrar H Mohmmed, Pallavi Ghildiyal, Alexey Yumashev, Ahmed Elawady, Sahel Sarabandi
Currently, it has been stated that psychiatric and psychological problems are equally paramount aspects of the clinical modulation and manifestation of both the central nervous and digestive systems, which could be used to restore balance. The present narrative review aims to provide an elaborate description of the bio-psycho-social facets of refractory functional gastrointestinal disorders, psychiatrists' role, specific psychiatric approach, and the latest psychiatric and psychological perspectives on practical therapeutic management...
June 19, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38897219/discontinuation-rate-of-lurasidone-and-quetiapine-extended-release-in-bipolar-depression
#12
JOURNAL ARTICLE
Taro Kishi, Kenji Sakuma, Shun Hamanaka, Yasufumi Nishii, Nakao Iwata
INTRODUCTION: Lurasidone (LUR) was compared with quetiapine extended release (QUE-ER) regarding 1-year discontinuation in patients with bipolar depression (n=317). METHODS: This is a retrospective cohort study. RESULTS: Although the time to all-cause discontinuation was estimated using the Kaplan-Meier survival curve with log-rank tests to compare treatment groups, no difference was found (p=0.317). The Cox proportional hazard model revealed that only the presence of adverse events (AEs) is associated with increased treatment discontinuation (p<0...
June 19, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38710208/advancements-in-non-dopaminergic-treatments-for-schizophrenia-a-systematic-review-of-pipeline-developments
#13
JOURNAL ARTICLE
Yuki Komatsu, Moe Takehara, Xenia Hart, Yuna Takahashi, Satoko Hori, Fumihiko Ueno, Hiroyuki Uchida
INTRODUCTION: Conventional antipsychotic drugs that attenuate dopaminergic neural transmission are ineffective in approximately one-third of patients with schizophrenia. This necessitates the development of non-dopaminergic agents. METHODS: A systematic search was conducted for completed phase II and III trials of compounds for schizophrenia treatment using the US Clinical Trials Registry and the EU Clinical Trials Register. Compounds demonstrating significant superiority over placebo in the primary outcome measure in the latest phase II and III trials were identified...
May 6, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38710207/cariprazine-orodispersible-tablet-a-new-formulation-for-cariprazine
#14
JOURNAL ARTICLE
Viktória Meszár, Gabriella Magyar, Gabriella Mészárosné Pásztor, Balázs Szatmári, Krisztina Péter, Lívia Marton, Zsófia B Dombi, Ágota Barabássy
INTRODUCTION: Cariprazine is an atypical dopamine receptor partial agonist antipsychotic available in the form of capsules. Although capsules are one of the most desirable routes of administration, there are certain situations (e. g., in an acute psychiatric setting, or when swallowing difficulties, or liquid shortages are present) when they cannot be administered. Therefore, alternative solutions like orodispersible tablets are needed. This study aimed to investigate the bioequivalence of a newly developed orodispersible tablet to the commercially available hard gelatine capsule of cariprazine 1...
May 6, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38710206/pentoxifylline-as-a-novel-add-on-therapy-for-major-depressive-disorder-in-adult-patients-a-randomized-double-blind-placebo-controlled-trial
#15
JOURNAL ARTICLE
Talar A Merza Mohammad, Tavgah A Merza Mohammad, Dyar M Salman, Halmat M Jaafar
BACKGROUND: Evidence indicates an association between immune dysregulation and major depressive disorder (MDD). Pentoxifylline (PTX), a phosphodiesterase inhibitor, has been shown to reduce pro-inflammatory activities. The aim of this study was to evaluate changes in depressive symptoms and pro-inflammatory markers after administration of PTX as an adjunctive agent to citalopram in patients with MDD. METHODS: One hundred patients were randomly assigned to either citalopram (20 mg/day) plus placebo (twice daily) (n=50) or citalopram (20 mg/day) plus PTX (400 mg) (twice daily) (n=50)...
May 6, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38698605/risk-phenotypes-comorbidities-pharmacotherapy-and-electroconvulsive-therapy-ect-in-a-cohort-with-difficult-to-treat-depression-in-comparison-to-an-unmedicated-control-group
#16
JOURNAL ARTICLE
Hannah B Maier, Anton Borchert, Alexandra Neyazi, Nicole Moschny, Rasmus Schülke, Gabriel L Bundies, Thorsten Folsche, Anastasia Gaspert, Johanna Seifert, Stefan Bleich, Maike Scherf-Clavel, Stefan Unterecker, Jürgen Deckert, Helge Frieling, Heike Weber
BACKGROUND: Approximately 15-25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT)...
May 2, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38714200/medical-cannabis-in-psychiatry
#17
EDITORIAL
Kirsten R Müller-Vahl, Georg Juckel
No abstract text is available yet for this article.
May 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38621701/blood-cell-count-ratios-at-baseline-are-associated-with-initial-clinical-response-to-clozapine-in-treatment-resistant-clozapine-na%C3%A3-ve-schizophrenia-spectrum-disorder
#18
JOURNAL ARTICLE
Vicent Llorca-Bofí, Miquel Bioque, Santiago Madero, Andrea Mallorquí, Cristina Oliveira, Marina Garriga, Eduard Parellada, Clemente García-Rizo
BACKGROUND: Clozapine is the recommended treatment for managing treatment-resistant schizophrenia (TRS), and immunological mechanisms may be involved in its unique antipsychotic efficacy. This study investigated whether baseline immune abnormalities measured with blood cell count ratios can predict the clinical response after initiating treatment with clozapine in patients with clozapine naïve TRS. METHODS: A longitudinal design was developed, involving 32 patients diagnosed with treatment-resistant, clozapine-naïve schizophrenia-spectrum disorder...
April 15, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38531375/comparable-psychotropic-prescription-rates-after-hospital-discharge-between-patients-with-covid-19-and-those-with-non-covid-19-related-respiratory-infection
#19
JOURNAL ARTICLE
Yuna Takahashi, Taisuke Yatomi, Naohito Yamaguchi, Kimio Yoshimura, Satoko Hori, Hiroyuki Uchida
INTRODUCTION: Whether psychiatric symptoms after recovery from coronavirus disease 2019 (COVID-19) are specific to this illness remains unclear. METHODS: In this retrospective study, the Diagnosis Procedure Combination data and outpatient clinic data were used for patients who received inpatient treatment in Saiseikai-affiliated hospitals for COVID-19 or other respiratory tract infections (non-COVID) from 2020 to 2022. The primary outcome was new prescriptions of psychotropic drugs after discharge (i...
March 26, 2024: Pharmacopsychiatry
https://read.qxmd.com/read/38471525/medicinal-use-of-different-cannabis-strains-results-from-a-large-prospective-survey-in-germany
#20
JOURNAL ARTICLE
Natalia Szejko, Eva Becher, Florian Heimann, Franjo Grotenhermen, Kirsten R Müller-Vahl
BACKGROUND: Up to now, it is unclear whether different medicinal cannabis (MC) strains are differently efficacious across different medical conditions. In this study, the effectiveness of different MC strains was compared depending on the disease to be treated. METHODS: This was an online survey conducted in Germany between June 2020 and August 2020. Patients were allowed to participate only if they received a cannabis -based treatment from pharmacies in the form of cannabis flowers prescribed by a physician...
March 12, 2024: Pharmacopsychiatry
journal
journal
28729
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.